Biomimetics is the imitation of the models, systems, and elements of nature for the purpose of solving complex human problems. 

    The term “biomimetics” derives from Ancient Greek: βίος (bios), life, and µίµησις , imitation.

Now based in Copenhagen, SB3000 ApS will have key operations in both the UK and Denmark.  

Over the last several years, SB3000 has developed composite ribbon technology based on the functions of Houghten’s Tea bag (1985) and the development of a superior mixing technology using ultrasound to create a robust platform technology. This disruptive technology has already been proven in a proof of concept model. 

Swedish based Swedish Biomimetics 3000 AB is a majority shareholder in SB3000 ApS, led by Lars Uno Larsson, a serial entrepreneur.  

SB3000 AB is a pioneer in the field of biomimetics which is to find, develop and launch technologies inspired by nature and to apply them to today’s  enviromental and climate change challenges .

SB3000 AB is also a majority investor in Swedish Biomimetics 3000 µMist Technologies Ltd, a disruptive innovative enviromental friendlier spray technology inspired by the Bombardier beetle. The µMist technology is set to disrupt a $200 billion spray market across a number of different industries.



Swedish Biomimetics 3000 is at the forefront of creating a platform technology that will advance not only therapeutic peptide production but also any form of chemistry or process based on a solid-liquid phase interaction including chromatography.

We believe that the µLOT® process will speed up
development, reduce cost and enable the synthesis of drugs currently not economically or technically possible to produce. At present the process is applicable to 80% of the market. We are developing the technology to cover the remaining market by including novel peptide designs such as lipid- and antibody-conjugations.

JENS BUKRINSKY, Chief R&D Officer, SB3000®


Zsolt Lavotha

ex. Pfizer, Wyeth, Rhone Poulenc, Orexo, ZEL Advisory Group

Torgeir Vaage

ex. ABG Sundal Collier, Directorships at misc. Biotech Boards

Chief R&D Officer 
Jens Bukrinski
ex. Novo Nordisk, Novozymes

Director of Business Operations
Lise Agersted

 ex. Novo Nordisk

Director of Technical Operations
Will Lennard

formerly Active Technologies, Lotus Engineering & Stewart GP F1 team

Chief Engineer
Simon Mulvany

formerly Lotus Engineering & AIC Labs

Karolina Lawitz

formerly Ferring, Astra Zeneca

Andy Prewer



Zsolt Lavotha
Chairman & CEO SB3000

ApS, ex Pfizer, Wyeth, Rhone Poulenc, Orexo, ZEL Advisory Group

Jo Pisani

ex PWC Pharma & Life Science Lead

MC. Luthman

Wistrand Advokat Burau, Bird & Bird

Prof Trevor Jones CBE
Hon FBPhS, Chair, Dir. Several global healthcare companies, ex-Head of R&D Wellcome

Dr. Alain Scarso
ex UCB, Lonza, PolyPeptide